TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Price, Forecast & Analysis
USA - NASDAQ:TNXP - US8902608392 - Common Stock
TNXP Key Statistics, Chart & Performance
The current stock price of TNXP is 17 USD. In the past month the price decreased by -19.77%. In the past year, price increased by 20.57%.
TNXP Latest News, Press Relases and Analysis
TNXP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.19 | 387.16B | ||
| AMGN | AMGEN INC | 14.64 | 172.38B | ||
| GILD | GILEAD SCIENCES INC | 14.51 | 147.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.59 | 104.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.61 | 69.69B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 868.04 | 58.03B | ||
| INSM | INSMED INC | N/A | 40.10B | ||
| NTRA | NATERA INC | N/A | 27.39B | ||
| BIIB | BIOGEN INC | 9.29 | 22.80B | ||
| INCY | INCYTE CORP | 16.51 | 20.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.01 | 20.30B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 36.45 | 15.11B |
Related stock screener links
About TNXP
Company Profile
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 81 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Company Info
TONIX PHARMACEUTICALS HOLDIN
26 Main Street, Suite 101
Chatham NEW JERSEY 07928 US
CEO: Seth Lederman
Employees: 81
Phone: 12129809155
TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ
What does TNXP do?
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 81 full-time employees. The company went IPO on 2010-03-29. Its development portfolio is focused on central nervous system (CNS) disorders. Its product candidates include TNX-102 SL, TNX-1300, TNX-2900, TNX-1900, TNX-1500, TNX-801, TNX-1800, TNX-4200, and TNX-1700. TNX-102 SL is for the management of fibromyalgia. Its CNS portfolio includes TNX-1300 (cocaine esterase), a biologic designed to treat cocaine intoxication that has a therapy designation. Its immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. The company markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg.
Can you provide the latest stock price for TONIX PHARMACEUTICALS HOLDIN?
The current stock price of TNXP is 17 USD. The price decreased by -2.35% in the last trading session.
Does TONIX PHARMACEUTICALS HOLDIN pay dividends?
TNXP does not pay a dividend.
How is the ChartMill rating for TONIX PHARMACEUTICALS HOLDIN?
TNXP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the GICS sector and industry of TNXP stock?
TONIX PHARMACEUTICALS HOLDIN (TNXP) operates in the Health Care sector and the Biotechnology industry.
Can you provide the market cap for TONIX PHARMACEUTICALS HOLDIN?
TONIX PHARMACEUTICALS HOLDIN (TNXP) has a market capitalization of 149.09M USD. This makes TNXP a Micro Cap stock.
Can you provide the upcoming earnings date for TONIX PHARMACEUTICALS HOLDIN?
TONIX PHARMACEUTICALS HOLDIN (TNXP) will report earnings on 2025-11-10, after the market close.
TNXP Technical Analysis
TNXP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to TNXP. No worries on liquidiy or solvency for TNXP as it has an excellent financial health rating, but there are worries on the profitability.
TNXP Financial Highlights
Over the last trailing twelve months TNXP reported a non-GAAP Earnings per Share(EPS) of -39.47. The EPS increased by 99.64% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -43.46% | ||
| ROE | -48.47% | ||
| Debt/Equity | 0 |
TNXP Forecast & Estimates
8 analysts have analysed TNXP and the average price target is 69.02 USD. This implies a price increase of 306% is expected in the next year compared to the current price of 17.
For the next year, analysts expect an EPS growth of 99.47% and a revenue growth -10.16% for TNXP